These pathways also play a role in VEGF-induced angiogenesis, and its receptor VEGFR2 is also one of the targets of sulfatinib; hence, the anti-tumor effect could be enhanced by inhibiting angiogenesis (52). This evidence concerns the gene KDR and neoplasm.